Literatura

  1. Vinson BR, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with Functional Dyspepsia and Irritable Bowel Syndrome. Gastroenterology 2013; 144: S682 (Mo1881)
  2. Ottillinger B, et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65-72
  3. Hunt R, Quigley E et al. World Gastroenterology Organisation Global Guidelines: Coping with common GI symptoms in the community. 
  4. El-Serag HB, Talley NJ. Systematic review: health related quality of life in functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 387-393
  5. Wagner H. Multitarget therapy - The future of treatment for more than just function dyspepsia. Phytomedicine 2006; 13: SV 122-129
  6. Andersen V, et al. Irritable Bowel Syndrome – The main Recommendations. Clinical Practice Guideline. Deutsches Ärzteblatt International. 2011; 108(44):751-60
  7. Vinson B. Development of Iberogast: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert 2009; pp. 167-189
  8. Saller R, et al. Iberogast: Eine modern phytotherapeutische Arzneimittelkombination zur Behandlung funktioneller Erkrankung des Magen-Darm-Trakts (Dyspepsie, Colon irritabile) – von der Pflanzenheilkunde zur “Evidence Based Phytotherapy” Forsch Komplementärmed Klass Naturheilkd 2002;9(suppl 1):1-20
  9. Kroll U, Cordes C, Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 2006; 13: SV 12-19
  10. Schemann M, Michel K, Hohenester B, Ruhl A. Region-specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90-99
  11. Allescher HD. Functional dyspepsia – A multicausal disease and its therapy. Phytomedicine 2006; SV 13: 2-11
  12. Liu CY, Müller MH, Glatzle J, Weiser D, Kelber O, Enck P, Grundy D, Kreis ME. The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759-764
  13. Heinle H, Hagelauer D, Pascht U, Kelber O, Weiser D. Intestinal spasmolytic effects of STW 5 (Iberogast) and its components. Phytomedicine 2006; 13: SV 75-79
  14. Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations. Aliment Pharmacol Ther 2004; 19: 271-279
  15. Nieber K, Michael S, Grotzinger K, Rauwald JW, Kelber O. Anti-inflammatory effect of STW 5, STW 6 and isolated extracts on the rat small intestine. Z Phytotherapie 2008; 29: S29
  16. Melzer J, Rösch W, Reichling J, et al. Metaanalysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20: 1279-1287
  17. Kelber O, Gaedcke F, Steinhoff B, Winterhoff H on behalf of the Working Group “Efficacy and Safety” of Kooperation Phytopharmaka, Bonn (Germany). Ethanol in herbal medicinal products in children. Pharm Ind 2008; 70: 1124-1127
  18. Hohenester B, Rühl A, Kelber O, Schemann M. the herbal preparation STW-5 (lberogast®) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil 2004; 16: 765-773
  19. Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogasts). Phytomedicine 2006; 13: SV 20-35
  20. Abdel-Aziz, H ., M . Schneider, W . Neuhuber, A . M . Kassem, S . Khailah, J . Muller, H . Gamaleldeen, A . Khairy, M . T . Khayyal, A . Shcherbakova, T . Efferth and G . Ulrich-Merzenich “GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis.” Mol Med, 2015. 21(1): 1011–1024.
  21. Pilichiewicz, A . N ., M . Horowitz, G . J . Holtmann, N . J . Talley and C . Feinle-Bisset "Relationship between symptoms and dietary patterns in patients with functional dyspepsia." Clin Gastroenterol Hepatol, 2009. 7(3): 317-22.
    von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study.” Am J Gastroenterol, 2007. 102(6): 1268–1275 .
  22. Abdel-Aziz, H ., M . Schneider, W . Neuhuber, A . M . Kassem, S . Khailah, J . Muller, H . Gamaleldeen, A . Khairy, M . T . Khayyal, A . Shcherbakova, T . Efferth and G . Ulrich-Merzenich “GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis.” Mol Med, 2015. 21(1): 1011–1024.
  23. Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017. 83(14/15): 1130–1140.
  24. Adarsh, M . B ., S . K . Sharma, K . K . Prasad, V . Dhir, S . Singh and S . K . Sinha " Esophageal manometry, esophagogastroduodenoscopy, and duodenal mucosal histopathology in systemic sclerosis." JGH Open, 2019. 3(3): 206-209.
  25. Allam, S ., D . Krueger, I . E . Demir, G . Ceyhan, F . Zeller and M . Schemann “Extracts from peppermint leaves, lemon balm leaves and in particular angelica roots mimic the pro-secretory action of the herbal preparation STW 5 in the human intestine.” Phytomedicine, 2015. 22(12): 1063–1070.
    Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of MultiTarget.” Dig Dis, 2017. 35 (Suppl 1): 18–24.
  26. Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy." Phytomedicine, 2006. 13 SV 2-11.
  27. Ammon, H . P ., O . Kelber and S . N . Okpanyi “Spasmolytic and tonic effect of Iberogast® (STW 5) in intestinal smooth muscle .” Phytomedicine, 2006. 13 (Suppl 5): 67–74.
  28. Angelicae radix, ESCOP monographs 2009.
  29. Anisi Fructus, ESCOP monographs 2014.
  30. Annibale. B ., G . Esposito and E . Lahner "A current clinical overview of atrophic gastritis." Expert Rev Gastroenterol Hpatol, 2020. 14(2): 93-102.
  31. Balaban, C . D . and B . J . Yates "What is nausea? A historical analysis of changing views." Auton Neurosci, 2017. 202: 5-17.
  32. Berg, L . K ., E . Fagerli, M . Martinussen, A . O . Myhre, J . Florholmen and R . Goll "Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test." Scand J Gastroenterol, 2013. 48(8): 936-43.
  33. Bhatia, V . and R . K . Tandon "Stress and the gastrointestinal tract ." J Gastroenterol Hepatol, 2005. 20(3): 332-9.
    Bleimann, H ., R . Hartmann "Therapy of Gastrointestinal Functional Disorders with Iberogast®." Der Kassenarzt, 1983; 23:52-59.
  34. Boeckxstaens, G ., M . Camilleri, D . Sifrim, L . A . Houghton, S . Elsenbruch, G . Lindberg, F . Azpiroz and H . P . Parkman "Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation ." Gastroenterology, 2016. 150: 1292-1304.
  35. Boland, M . "Human digestion - a processing perspective ." J Sci Food Agric, 2016. 96: 2275-283.
  36. Bonaterra, G . A ., O . Kelber, D . Weiser and R . Kinscherf “Mechanisms of the antiproliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro.” Phytomedicine, 2013. 20(8–9): 691–698.
  37. Bonaterra, G ., R . Kinscherf, O . Kelber, D . Weiser and J . Metz “Antiinflammatorische und antiproliferative Wirkung von Iberogast® in vitro.” Z Gastroenterol, 2008. 46(09): P352.
  38. Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis.” Neurogastroenterology & Motility, 2009. 21(6): 632–e625.
  39. Bredenoord, A . J . and A . J . P . Smout "Physiologic and pathologic belching ." Clin Gastroenterol Hepatol, 2007. 5(7): 772-5.
  40. Bremer, W ., F . Fischer and K . Nicolay "Gastrointestinal Illnesses - Therapy with Iberogast® " Z. Allg. Med., 1983. 59: 1706-1709.
  41. Brückel, M . H ., W . Gisevius "Iberis Amara Helps in Cases of Functional Stomach Complaints." Ärztl. Praxis, 1984. 36: 494.
  42. Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rabbit.” 2003. Sequani Study no: VEB0003.
  43. Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rat.” 2003 . Sequani Study no: VEB0006 [Module 4 .2 .3 .5 .1 .3].
  44. Burns, L . M . “Oral (gavage) developmental toxicity study in the rabbit.” 2003. Sequani Study no: VEB0004.
  45. Burns, L . M . “Oral (gavage) developmental toxicity study in the rat.” 2003. Sequani Study no: VEB0008 [Module 4 .2 .3 .5 .1 .2].
  46. Burns, L . M . “Oral (gavage) fertility and general reproductive performance dose ranging study in the rat .” 2003. Sequani Study no: VEB0005 [Module 4 .2 .3 .5 .1 .1].
  47. Burns, L . M . “Oral (gavage) maximum tolerated dose (MTD) study in the rabbit .” 2003. Sequani Study no: VEB0002 .
    Burns, L . M . “Oral (gavage) pre- and post-natal developmental toxicity study in the rat .” 2003. Study no: VEB0009 [Module 4 .2 .3 .5 .3 .1].
  48. Burri, E ., E . Barba, J . W . Huaman, D . Cisternas, A . Accarino, A . Soldevilla, J . R . Malagelada, and F . Azpiroz "Mechanisms of postprandial abdominal bloating and distension in functional dyspepsia." Gut, 2014 . 63(3): 395-400.
  49. Bustos, M ., R . Venkataramanan and Steve Caritis "Nausea and vomiting of pregnancy - What's new? " Auton Neurosci, 2017. 202: 62-72.
  50. Bytzer, P . and N . J . Talley “Dyspepsia .” Ann Intern Med, 2001 . 134(9 Pt 2): 815–822.
  51. Camilleri, M ., B . Coulie and J . F . Tack “Visceral hypersensitivity: facts, speculations, and challenges.” Gut, 2001. 48(1): 125–131.
  52. Carvalho, R . V . B ., S . L . S . Lorena, J . R . de Souza Almeida and M . A . Mesquita "Food intolerance, diet composition, and eating patterns in functional dyspepsia patients." Dig Dis Sci, 2010. 55(1): 60-5.
  53. Carvi fructus, ESCOP monographs 2003.
  54. Catassi, G ., E . Lionetti, S . Gatti and C . Catassi "The Low FODMAP Diet: Many Question Marks for a Catchy Acronym." Nutrients, 2017. 9(3): 292.
  55. Surdea/Blaga, T,D.E. Negrutiu, M.Palage and D.L. Dimitrascu @Food and Gastroesophageal Reflux Disease.(Curr Med Chem, 2019. 26(19): 3497-3511.

Iberohexa® - Naravna in učinkovita rešitev za vaše prebavne težave

VEČ INFORMACIJ
Iberohexa
Kobieta trzymająca się za brzuch.

Iberohexa: Celovit pristop pri prebavnih težavah

Izkoristite moč narave z 6 zdravilnimi rastlinami, ki delujejo z roko v roki. Učinkovita, klinično dokazana rešitev.2

Odkrijte več
Dwie śmiejące się kobiety

Ali imate vprašanja o zdravilu Iberohexa?

Tu boste našli hiter pregled najpomembnejših tem.

Odkrijte več
Iberohexa stojący obok szklanki z wodą i wazonu z kwiatkiem.

Opažate simptome prebavnih težav zaradi stresa? Iberohexa lahko pomaga.

Prebavne težave lahko resno vplivajo na vsakodnevno življenje. Odkrijte več o tem, kako pride do njih in kaj lahko v zvezi z njimi storite.

Odkrijte več